Totus Medicines

Totus Medicines

Private
Emeryville, CaliforniaHealthcare & Life Scienceshttps://www.totusmedicines.com

Last Round

Series B

Dec 15, 2023

Total Funding Raised

$107.5M

Company Overview

Totus Medicines is a biotechnology company that develops innovative chemical biology technologies to create therapeutics for previously untreatable diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Infrastructure

Keywords

covalent drug discoveryundruggable targetssmall molecule drug discoveryAI drug discoverydrug discovery platformDNA-encoded libraryDEL screeningcovalent inhibitorsprecision oncologyPI3Kα inhibitorhigh-throughput screeningpharmaceutical partnershipscellular screeningbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Totus Medicines Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Totus Medicines Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BDec 15, 2023
Series ADec 9, 2021

Key People

Founding team and executive leadership

Nassim Usman

President Chief Executive Officer

Executive Team

Simon Harnest

Chief Financial Officer

Executive Team

Totus Medicines Investors

Notable investors and investment history

InvestorRounds
DCVC BioSeries A, Series B
Camford CapitalSeries A, Series B
Northpond VenturesSeries B, Series A
Social Impact CapitalSeries A, Seed
University of MinnesotaSeries B
Northpond VenturesSeries B, Series A
Camford CapitalSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Presenting data on covalent IRF5 inhibitor at AAI IMMUNOLOGY2026.

  • Apr 16, 2026

    Presenting data at the AAI IMMUNOLOGY2026 event.

Totus Medicines Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Totus Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Totus Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersEmeryville, California
Employee Range40
Year Founded2019
Last FundingDec 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.